CYBERDYNE (8C4) Stock Price & Analysis
8C4 Stock Chart & Stats
- Day’s Range
- EUR 1.07 - EUR 1.07
- 52-Week Range
- EUR 0.90 - EUR 2.10
- Previous Close
- EUR 1.12
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 229.94M
- Enterprise Value
- EUR 37.03B
- Total Cash (Recent Filing)
- EUR 13.12B
- Total Debt (Recent Filing)
- EUR 540.00M
- Price to Earnings (P/E)
- 147.7
- Beta
- 0.73
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue Growth
The sharp increase in trailing revenue indicates expanding commercial activity for CYBERDYNE’s products and services. If sustained, stronger sales can improve operating leverage, support broader adoption of its healthcare technologies, and provide a larger base from which to build durable future earnings.
Solid Gross Margin
A gross margin near 49% suggests CYBERDYNE’s products and related services retain meaningful value after direct costs. This provides a foundation for improving profitability as revenue scales, although the benefit will depend on whether operating expenses become more efficiently covered over time.
Very Low Financial Leverage
Minimal leverage gives CYBERDYNE substantial financial flexibility and reduces exposure to interest costs or refinancing pressure. A conservatively funded balance sheet can help the company continue developing and commercializing its robotics portfolio while providing resilience if cash generation remains uneven.
Bears Say
Negative Operating And Free Cash Flow
Current cash burn shows that reported business activity is not yet converting into internally generated funds. Persistently negative operating and free cash flow could require CYBERDYNE to draw on its balance sheet, limiting the resources available for product development, commercialization, and expansion.
Operating Profitability Remains Weak
Negative EBIT and EBITDA margins indicate that CYBERDYNE is not yet covering its operating cost base through recurring business performance. This weakens the durability of its earnings profile and means revenue growth must continue while costs improve before scale can translate into dependable operating profits.
Low Returns On Invested Capital
A very modest return on equity suggests the company is generating limited economic returns from its capital base despite recent improvement. Prior negative returns reinforce that profitability has not yet become consistent, which may constrain long-term value creation until operating performance strengthens.
CYBERDYNE News
8C4 FAQ
What was CYBERDYNE’s price range in the past 12 months?
What is CYBERDYNE’s market cap?
When is CYBERDYNE’s upcoming earnings report date?
How were CYBERDYNE’s earnings last quarter?
Is CYBERDYNE overvalued?
Does CYBERDYNE pay dividends?
What is CYBERDYNE’s EPS estimate?
How many shares outstanding does CYBERDYNE have?
What happened to CYBERDYNE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CYBERDYNE?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CYBERDYNE
Headquartered in Tsukuba, Japan, and founded in 2004, CYBERDYNE Inc. is dedicated to the ongoing research, development, production, sales, leasing, and maintenance of sophisticated equipment and systems, primarily for the medical and defense sectors within Japan. Their innovative product line features the Hybrid Assistive Limb (HAL), available in medical variants for lower limbs and single joints, as well as non-medical versions designed for lower limbs, single joints, and lumbar support. The company also supplies HAL peripherals, robotic cleaners, and autonomous transport robots for factories, offices, and various other indoor environments. A notable technological offering is Acoustic X, a high-speed light pulse LED array that facilitates real-time photoacoustic imaging. Complementing their hardware, CYBERDYNE provides specialized treatments and programs such as Cybernics Treatment, which utilizes HAL to restore or enhance function for individuals suffering from conditions like spinal cord injuries, strokes, and neuromuscular disorders. They additionally offer HAL FIT and Neuro HALFIT to improve brain-nerve-musculoskeletal and general physical functions, respectively, and MTX Neuro HAL Plus to optimize brain-nerve performance in athletes. Furthermore, the company extends its expertise to critical areas including disaster rescue operations, heavy industrial labor assistance, and contributions to the entertainment industry.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Yoshiyuki Sankai
- Employees
- 203
- Website
- www.cyberdyne.jp
- Address
- 2-2-1, Gakuen-Minami, Tsukuba, IB, 305-0818, JP
CYBERDYNE (8C4) Earnings & Revenues
8C4 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |
